RxDoctor Payments Data

Astrid Werner, MD

Ophthalmology · Boston, MANPI 1831503598

Payments from drug & device makers

$1,375in general payments, 2019–2025

Across 35 payments — averaging $39.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$551
  • Tarsus Pharmaceuticals, Inc.$221
  • Sight Sciences, Inc.$143
  • Glaukos Corporation$143
  • Alcon$113
  • Bausch & Lomb Americas Inc.$75
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$1,33097%
  • Gifts$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,375 in reported general payments places this provider in the 55th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$268,717
Medicare patients
793
Services billed
2,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate158$95,205
LumiganBimatoprost96$44,415
RestasisCyclosporine22$24,061
RocklatanNetarsudil Mesylat/Latanoprost33$23,645
Latanoprost1,204$17,262
Brimonidine Tartrate274$16,703
Methazolamide55$12,294
Dorzolamide-TimololDorzolamide/Timolol/Pf71$10,446
Timolol Maleate397$9,202
CombiganBrimonidine Tartrate/Timolol16$8,196
Timolol MaleateTimolol Maleate/Pf14$8,028
Alphagan PBrimonidine Tartrate22$7,807
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat423$7,283
VyzultaLatanoprostene Bunod16$7,173
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$4,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$35$118,850191 claims
AbbVieLumigan, Restasis, Combigan, Alphagan P$551$84,480156 claims
Bausch & Lomb Americas Inc.Vyzulta$75$7,17316 claims
AlconSimbrinza$113$4,24618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →